Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Compugen Ltd. (CGEN : NSDQ)
 
 • Company Description   
Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery.

Number of Employees: 74

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.78 Daily Weekly Monthly
20 Day Moving Average: 262,147 shares
Shares Outstanding: 89.24 (millions)
Market Capitalization: $158.84 (millions)
Beta: 2.57
52 Week High: $2.66
52 Week Low: $1.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 18.67% 13.52%
12 Week 41.27% 15.25%
Year To Date 16.34% 10.28%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Azrieli Center 26 Harokmim Street Building D
-
Holon,L3 5885849
ISR
ph: 972-3765-8585
fax: 972-3765-8555
ir@cgen.com http://www.cgen.com
 
 • General Corporate Information   
Officers
Anat Cohen-Dayag - Chief Executive Officer;President and Director
Paul Sekhri - Chairman of the Board of Directors
David Silberman - Chief Financial Officer
Pierre Ferre - Senior Vice President; Preclinical Development and
Mathias Hukkelhoven - Director

Peer Information
Compugen Ltd. (CORR.)
Compugen Ltd. (RSPI)
Compugen Ltd. (CGXP)
Compugen Ltd. (BGEN)
Compugen Ltd. (GTBP)
Compugen Ltd. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M25722105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 89.24
Most Recent Split Date: (:1)
Beta: 2.57
Market Capitalization: $158.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.78
Price/Cash Flow: -
Price / Sales: 5.76
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -14.29%
Sales Growth
vs. Year Ago Period: -10.75%
vs. Previous Quarter: 55.27%
ROE
06/30/25 - -
03/31/25 - -24.51
12/31/24 - -24.39
ROA
06/30/25 - -
03/31/25 - -12.19
12/31/24 - -12.31
Current Ratio
06/30/25 - -
03/31/25 - 5.09
12/31/24 - 5.26
Quick Ratio
06/30/25 - -
03/31/25 - 5.09
12/31/24 - 5.26
Operating Margin
06/30/25 - -
03/31/25 - -51.27
12/31/24 - -51.07
Net Margin
06/30/25 - -
03/31/25 - -51.27
12/31/24 - -51.07
Pre-Tax Margin
06/30/25 - -
03/31/25 - -34.78
12/31/24 - -34.84
Book Value
06/30/25 - -
03/31/25 - 0.64
12/31/24 - 0.62
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©